Ivanna Saucedo
Medical · San Antonio, TXNPI 1811442593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 688 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 688 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Galderma Laboratories, L.p.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$826
- Pfizer$747
- Dermavant Sciences, Inc.$715
- plus $6K from 26 others
What the payments were for
- Food & beverage$12,46696%
- Education$4924%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 110 | $2,291 |
| Galderma Laboratories, L.p. | 66 | $1,397 |
| Regeneron Healthcare Solutions, Inc. | 87 | $1,141 |
| E.r. Squibb & Sons, L.L.C. | 34 | $826 |
| Pfizer | 59 | $747 |
| Dermavant Sciences, Inc. | 52 | $715 |
| Lilly USA, LLC | 30 | $714 |
| Johnson & Johnson | 22 | $631 |
| UCB, Inc. | 23 | $625 |
| Novartis | 28 | $542 |
| Sun Pharmaceutical Industries Inc. | 28 | $453 |
| Incyte Corporation | 25 | $437 |
| LEO Pharma Inc. | 26 | $401 |
| Sanofi | 17 | $382 |
| Krystal Biotech Inc | 16 | $366 |
| Arcutis Biotherapeutics, Inc. | 13 | $330 |
| Boehringer Ingelheim | 7 | $172 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $171 |
| Organon | 8 | $117 |
| Biofrontera Inc. | 7 | $102 |
| Amgen | 3 | $76 |
| Fresenius Kabi USA, LLC | 3 | $71 |
| VYNE Pharmaceuticals Inc. | 2 | $41 |
| Verrica Pharmaceuticals Inc. | 2 | $33 |
| Kerecis Limited | 2 | $30 |
| Cipher Pharmaceuticals US LLC | 1 | $28 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $25 |
| Botanix SB Inc | 1 | $22 |
| Octapharma USA, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Nobelpharma America, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,958 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $103,769 |
| Clobetasol Propionate | 53 | $3,258 |
| Clindamycin Phosphate | 28 | $1,230 |
| Ketoconazole | 84 | $1,112 |
| Triamcinolone Acetonide | 57 | $537 |
| Doxycycline Monohydrate | 20 | $344 |
| Nystatin | 20 | $289 |
| Ammonium Lactate | 12 | $288 |
| Hydrocortisone | 20 | $97 |
| Ibuprofen | 12 | $77 |
Paid to pharmacies, not to this prescriber.
Other medical in San Antonio
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
- John KodoskySan Antonio$58K
- Amanda MillerSan Antonio$27K
- Felipe GalvanSan Antonio$26K
- Ledyenska BallesterosSan Antonio$22K
- Daniella ArellanoSan Antonio$15K
- Robert SchonhoffSan Antonio$14K
- Tanya GainesSan Antonio$14K
- Mui LeeSan Antonio$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.